SCHEMBL5331

SCHEMBL5331

CCCCCC(=O)OC1CC(=O)C=C2CC[C@H]3[C@@H]4CC[C@H](C(C)=O)[C@@]4(C)CC[C@@H]3[C@]21C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.62
CYP3A4 P08684 7/20 0.54
MAPT P10636 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 4/20 0.54
NR1I2 O75469 4/20 0.54
CYP2C9 P11712 3/20 0.54
TSHR P16473 3/20 0.54
HIF1A Q16665 3/20 0.54
NR3C1 P04150 3/20 0.54
PGR P06401 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPK1 P28482 2/20 0.54
CYP2C19 P33261 2/20 0.54
AR P10275 2/20 0.54
ADORA3 P0DMS8 2/20 0.54
PDE3A Q14432 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
KDM4E B2RXH2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571724 1.00 LMNA (0.62) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL353517 0.99 LMNA (0.64) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL5425553 0.99 LMNA (0.64) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL8015127 0.97 LMNA (0.60) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL2561836 0.94 CYP3A4 (0.56) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL28255051 0.93 CYP3A4 (0.59) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL976275 0.90 CYP3A4 (0.56) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL11023737 0.90 CYP3A4 (0.60) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL2042111 0.88 CYP3A4 (0.58) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1
SCHEMBL28137569 0.88 CYP3A4 (0.54) LMNACYP3A4MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 17220 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
EP-4525938-B1 RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS BAYER AG (DE) 2026-03-11 EP claimed
US-20260027215-A1 COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV RECEPTIVE BIO INC (US) 2026-01-29 US claimed
US-20260022117-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS INC (US) 2026-01-22 US claimed
US-20260000613-A1 INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS FORDOZ PHARMA CORP. (US) 2026-01-01 US claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US claimed
US-20250332274-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS UNIV YALE (US) 2025-10-30 US claimed
US-20250326778-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2025-10-23 US claimed
CN-1088778-A Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration NOVEN PHARMA (US) 1994-07-06 CN claimed
EP-0591432-A1 SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION NOVEN PHARMACEUTICALS, INC. (US) 1994-04-13 EP claimed
WO-1994004702-A2 IMPROVED DETECTION AND THERAPY OF LESIONS WITH BIOTIN/AVIDIN CONJUGATES IMMUNOMEDICS, INC. (US) 1994-03-03 WO claimed
EP-0538443-A4 METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS 1993-12-08 EP claimed
WO-1993019668-A1 METHOD AND KIT FOR IMAGING AND TREATING ORGANS AND TISSUES IMMUNOMEDICS, INC. (US) 1993-10-14 WO claimed
US-5211952-A Drug delivery of gonadotropin hormone releasing hormones for time release UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1993-05-18 US claimed
EP-0538443-A1 METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. UNIV SOUTHERN CALIFORNIA (US) 1993-04-28 EP claimed
WO-1993000058-A1 SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION NOVEN PHARMACEUTICALS, INC. (US) 1993-01-07 WO claimed
WO-1992018107-A1 METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1992-10-29 WO claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 EP claimed